Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63.

Slides:

Advertisements

Similar presentations

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Advertisements

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ﬀ ects of lowering LDL cholesterol with simvastatin plus.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Weng TC, et al. J Clin Pharm Ther 2010;35:

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Lipid Management in Stroke : Statin and Other Lipid Modifying Agents Professor Pierre Amarenco INSERM U-698 and Paris-Diderot University Department of.

The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial 颈动脉内膜切除术无症状狭窄多中心随机试验.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

The ALERT Trial.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Cholesterol Lowering and CV Risk: Meta-analyses

Statin Myopathy (AHA/ACC/NHLBI)

Scandinavian Simvastatin Survival Study (4S)

TNT: Baseline and final LDL cholesterol levels

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Beyond Statin Therapy.

Baseline characteristics of HPS participants by prior diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

TNT Study: Baseline Characteristics of the Patients

New LDL-C Lipid Targets

ASCOT-BPLA: Primary and secondary end points

Jun M, et al. Lancet 2010 Epub May 10

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Updates in Cardiovascular Medicine

Statins for prevention of stroke

Préparation ESC Septembre

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Potential mechanisms whereby statins may reduce the risk of stroke

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

New Lipid-Lowering Therapies

Cause of death Treatment-arm events, % (n=45 054)

Characteristics of included studies

PROSPER: trial design

MATRIX: Radial vs. Femoral

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Baseline characteristics of study population

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Characteristics of selected major statin trials Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Updated meta-analysis of major statin trials that assessed the effect of statins on fatal and non-fatal stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Updated meta-analysis of major statin trials that assessed the effect of statins on fatal stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Updated meta-analysis of major statin trials that assessed the effect of statins on haemorrhagic stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Association between reduction in LDL cholesterol concentration with stroke incidence among the major statins trials Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Meta-analysis of statin trials that assessed the effect of intensive lipid-lowering therapy versus standard statin therapy on incidence of fatal and non-fatal stroke and on major cardiovascular events Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63